Clinical Trials Logo

Clinical Trial, Phase I clinical trials

View clinical trials related to Clinical Trial, Phase I.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04375267 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

LuPARP
Start date: April 23, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent survival of the tumour cells, making them more sensitive to β-emission and increase the probability of tumour cell death.